1. 1. Patient Presentation
1.1. John D., 28-year-old male
1.2. Found unconscious due to opioid overdose
1.3. History of schizophrenia and opioid use disorder
1.4. Suicide note found, detailing hopelessness and paranoia
1.5. Emergency care: Naloxone administration and psychiatric evaluation
1.6. Transferred to inpatient psychiatric unit
2. 2. Understanding the Complex Disease Process
2.1. Schizophrenia (American Psychiatric Association, 2019)
2.1.1. Risk Factors
2.1.1.1. Genetic predisposition
2.1.1.2. Early childhood trauma
2.1.1.3. Prenatal complications
2.1.1.4. Substance use disorder
2.1.2. Signs & Symptoms
2.1.2.1. Positive Symptoms
2.1.2.1.1. Hallucinations (auditory, visual, tactile)
2.1.2.1.2. Delusions (paranoia, grandiosity)
2.1.2.1.3. Disorganized speech and erratic behavior
2.1.2.2. Negative Symptoms
2.1.2.2.1. Avolition (lack of motivation)
2.1.2.2.2. Alogia (reduced speech output)
2.1.2.2.3. Anhedonia (inability to feel pleasure)
2.1.2.2.4. Affective flattening (lack of emotional expression)
2.1.2.3. Cognitive Symptoms
2.1.2.3.1. Impaired executive function
2.1.2.3.2. Working memory deficits
2.1.2.3.3. Decreased attention and concentration
2.1.3. Definition: Chronic psychiatric disorder affecting cognition, perception, and behavior
2.1.3.1. Diagnostic Criteria
2.1.3.1.1. Requires two or more symptoms persisting for six months
2.2. Suicide Attempt and Mental Health Crisis (Pompili et al., 2007)
2.2.1. Increased risk in individuals with schizophrenia and substance use disorders
2.2.1.1. Risk Factors
2.2.1.1.1. History of psychiatric illness
2.2.1.1.2. Substance abuse
2.2.1.1.3. Social isolation, unemployment
2.2.1.1.4. Previous suicide attempts
2.2.2. Signs & Symptoms
2.2.2.1. Expressions of hopelessness
2.2.2.2. Social withdrawal
2.2.2.3. Giving away personal belongings
2.2.2.4. Reckless behavior and increased substance use
2.2.3. Diagnostic Tools
2.2.3.1. Columbia-Suicide Severity Rating Scale (C-SSRS)
2.2.3.2. Beck Depression Inventory
2.3. Opioid Use Disorder (OUD) (Hunt et al., 2018)
2.3.1. Definition: Chronic, relapsing disorder with compulsive opioid consumption
2.3.1.1. Diagnostic Criteria
2.3.1.1.1. DSM-5 criteria: cravings, tolerance, withdrawal, continued use despite harm
2.3.2. Risk Factors
2.3.2.1. Chronic pain
2.3.2.2. Family history of substance use
2.3.2.3. Co-occurring psychiatric disorders
2.3.2.4. History of trauma or adverse childhood experiences
2.3.3. Signs & Symptoms
2.3.3.1. Intense cravings and loss of control
2.3.3.2. Withdrawal symptoms (nausea, tremors)
2.3.3.3. Drug-seeking behaviors
2.3.3.4. Increased overdose risk, especially with alcohol
3. 3. Clinical Assessment and Diagnostic Findings
3.1. Medical History
3.1.1. Schizophrenia diagnosed at age 22
3.1.2. Multiple psychiatric hospitalizations
3.1.3. Opioid dependence and prior rehabilitation attempts
3.1.4. History of non-adherence to antipsychotic medication
3.1.5. Previous suicide attempt two years prior
3.2. Diagnostic Tests
3.2.1. Toxicology Screen: Positive for opioids and benzodiazepines
3.2.2. Complete Blood Count (CBC): Mild anemia, potential nutritional deficiencies
3.2.3. Electrolytes & Kidney Function: Elevated creatinine levels (dehydration)
3.2.4. CT Brain Scan: No acute abnormalities detected
3.3. Physical Assessment Findings
3.3.1. Glasgow Coma Scale (GCS): 10/15
3.3.2. Pinpoint pupils, depressed respiratory rate (opioid overdose signs)
3.3.3. Slurred speech, disorganized thought process
3.3.4. Poor hygiene, malnourished appearance
4. 4. Nursing Plan of Care
4.1. Immediate Nursing Interventions
4.1.1. Airway & Breathing Support
4.1.1.1. Monitor oxygen saturation
4.1.1.2. Administer naloxone for opioid-induced respiratory depression
4.1.2. Suicide Precautions
4.1.2.1. 1:1 suicide watch to prevent self-harm
4.1.3. Medication Management
4.1.3.1. Restart antipsychotic treatment with close adherence monitoring
4.2. Long-Term Nursing Interventions
4.2.1. Medication Adherence
4.2.1.1. Transition to long-acting injectable antipsychotics for improved compliance
4.2.2. Substance Use Recovery
4.2.2.1. Medication-Assisted Treatment (MAT) with buprenorphine or methadone
4.2.3. Psychotherapy and Cognitive Behavioral Therapy (CBT)
4.2.3.1. Coping strategies for schizophrenia and addiction
4.2.4. Social Support and Rehabilitation
4.2.4.1. Coordinate with social workers for housing and employment assistance
4.2.5. Relapse Prevention
4.2.5.1. Encourage participation in support groups like Narcotics Anonymous
5. 5. Patient Education
5.1. Disease Understanding
5.1.1. Schizophrenia, opioid use disorder, and their interaction
5.2. Medication Adherence
5.2.1. Importance of antipsychotic and MAT adherence
5.3. Lifestyle Modifications
5.3.1. Structured routines, proper nutrition, exercise
5.4. Suicide Risk Awareness
5.4.1. Recognizing warning signs
5.4.2. When to seek immediate medical attention
6. 6. Collaboration & Interdisciplinary Care
6.1. Psychiatrists (American Psychiatric Association, 2019)
6.1.1. Medication management
6.1.2. Adjusting antipsychotics and MAT for substance use disorder
6.2. Social Workers (Green et al., 2007)
6.2.1. Housing and employment assistance
6.2.2. Connecting with community resources
6.2.3. Ensuring continuity of care after discharge
6.3. Addiction Specialists (Hunt et al., 2018)
6.3.1. Medication-Assisted Treatment (MAT) for opioid use disorder
6.3.2. Overdose prevention strategies
6.3.3. Harm reduction education
6.4. Therapists & Psychologists (Pompili et al., 2007)
6.4.1. Cognitive Behavioral Therapy (CBT) for managing schizophrenia and substance use disorder
6.4.2. Trauma-informed therapy for past adverse experiences
6.4.3. Identifying triggers and developing coping strategies
6.5. Nurses
6.5.1. Implementing safety precautions (suicide watch, substance withdrawal monitoring)
6.5.2. Educating the patient on medications and lifestyle modifications
6.5.3. Advocating for patient-centered care and ensuring adherence to treatment plans
6.6. Case Managers
6.6.1. Coordinating follow-up care after discharge
6.6.2. Ensuring access to medications and therapy appointments
6.7. Peer Support Groups
6.7.1. Narcotics Anonymous (NA) for substance use disorder recovery
6.7.2. Schizophrenia peer support groups for social integration